Physician profile
Jacob S Morrill
NPI 1770184434
$4,907.41
in general payments reported to CMS, 2019-2025
26 companies · $1,214 in 2025
The $1,214 reported for 2025 was more than what 86% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $657 · 2022: $850 · 2023: $942 · 2024: $1,244 · 2025: $1,214.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,349 · Education: $50.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,349.25 |
| Education | $50.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,408.56 | 2021-2025 | |
| Janssen Biotech, INC. | $901.93 | 2021-2025 | Stelara, Tremfya, Simponi Aria |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $606.53 | 2021-2025 | Xifaxan, Trulance |
| Takeda Pharmaceuticals U.S.A., INC. | $585.15 | 2021-2025 | Entyvio, Gattex, Eohilia |
| Aimmune Therapeutics, INC. | $156.39 | 2024-2025 | Zenpep |
| Boston Scientific Corporation | $146.48 | 2023-2024 | Exalt Model D |
| Ipsen Biopharmaceuticals, INC | $137.46 | 2023-2025 | Iqirvo, Bylvay |
| Ardelyx, INC. | $132.21 | 2024-2025 | Ibsrela |
| Lilly USA, LLC | $107.52 | 2023-2025 | Omvoh |
| Madrigal Pharmaceuticals | $90.98 | 2024-2025 | Rezdiffra, Resmetirom |
| Intercept Pharmaceuticals, INC. | $88.71 | 2021-2025 | Ocaliva |
| Genzyme Corporation | $85.54 | 2023-2025 | |
| Celgene Corporation | $83.43 | 2021-2024 | Zeposia |
| Phathom Pharmaceuticals, INC. | $71.58 | 2024-2025 | Voquezna |
| Braintree Laboratories, INC. | $48.32 | 2023-2024 | Suflave, Sutab |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $45.11 | 2021-2022 | |
| Steris Corporation | $43.39 | 2025 | |
| Merck Sharp & Dohme LLC | $30.68 | 2021 | |
| Ambu INC. | $22.09 | 2022 | |
| Novo Nordisk INC | $21.86 | 2025 | Wegovy |
| Alnylam Pharmaceuticals INC. | $19.46 | 2024 | Givlaari |
| Organon LLC | $16.58 | 2024 | |
| Ucb, INC. | $15.34 | 2023 | Cimzia |
| Qol Medical, LLC | $15.00 | 2024 | Sucraid |
| Ferring Pharmaceuticals INC. | $14.15 | 2023 | Rebyota |
| Pfizer INC. | $12.96 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jacob Morrill listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.